WallStSmart

Merck & Company Inc (MRK)vsVarex Imaging Corp (VREX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 7689% more annual revenue ($67.38B vs $865.00M). MRK leads profitability with a 3.6% profit margin vs 2.6%. MRK appears more attractively valued with a PEG of 2.82. VREX earns a higher WallStSmart Score of 55/100 (C-).

MRK

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

VREX

Buy

55

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 4.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-72.9%)

Margin of Safety

-72.9%

Fair Value

$84.87

Current Price

$146.99

$62.12 premium

UndervaluedFair: $84.87Overvalued
VREXUndervalued (+13.6%)

Margin of Safety

+13.6%

Fair Value

$15.76

Current Price

$18.27

$2.51 discount

UndervaluedFair: $15.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$368.89B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

VREX2 strengths · Avg: 9.0/10
EPS GrowthGrowth
453.4%10/10

Earnings expanding 453.4% YoY

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

VREX4 concerns · Avg: 3.8/10
P/E RatioValuation
34.8x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
3.7%4/10

3.7% revenue growth

Altman Z-ScoreHealth
1.654/10

Distress zone — elevated risk

Market CapQuality
$783.03M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : VREX

The strongest argument for VREX centers on EPS Growth, Price/Book.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : VREX

The primary concerns for VREX are P/E Ratio, Revenue Growth, Altman Z-Score. Thin 2.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

VREX carries more volatility with a beta of 1.03 — expect wider price swings.

MRK is growing revenue faster at 4.7% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VREX scores higher overall (55/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Varex Imaging Corp

HEALTHCARE · MEDICAL DEVICES · USA

Varex Imaging Corporation designs and manufactures X-ray imaging components. The company is headquartered in Salt Lake City, Utah.

Visit Website →

Want to dig deeper into these stocks?